CASI Stock Plummets on Nasdaq Delisting Notice

CASI Pharmaceuticals Faces Delisting, Stock Drops 56.7%

CASI Pharmaceuticals Inc shares plunged 56.7% after the company announced it received a determination letter from the Nasdaq Hearings Panel to delist its securities. The decision stems from the biopharmaceutical company's failure to meet continued listing requirements.

Details of the Nasdaq Delisting

According to the company's disclosure, trading of its securities will be suspended at the open of business on February 26, 2026. The delisting process will follow after the completion of applicable procedures. CASI Pharmaceuticals has stated that it does not intend to request a review of the Panel's decision.

Impact on Trading and Company Operations

Following its removal from Nasdaq, CASI expects its ordinary shares to be quoted on the over-the-counter market operated by OTC Markets Group Inc. This move could potentially allow a trading market to continue. However, delisting from a major exchange typically results in reduced liquidity and visibility. The company noted the delisting will have no significant impact on its core operations.

Outlook for CASI Shares

Investors will now monitor the stock's transition to the OTC market, where trading volumes are generally lower. While the company's focus on developing CID-103 remains, the delisting marks a significant change in its public market status.

FAQ

Q: Why is CASI Pharmaceuticals being delisted from Nasdaq?
A: The company was delisted for failing to satisfy Nasdaq's continued listing conditions.

Q: Where will CASI stock be traded after the delisting?
A: CASI expects its shares will be quoted on the over-the-counter market, also known as the OTC market.

Source: Investing.com